DURECT Corporation

341 articles with DURECT Corporation

• DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

  7/22/2021

  DURECT Corporation announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.

• DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit

  7/14/2021

  DURECT Corporation announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021.

• DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)

  6/9/2021

  DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL)  to be held virtually June 23-26 , 2021. 

• DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs

  5/4/2021

  DURECT Corporation announced financial results for the three months ended March 31, 2021 and provided a corporate update.

• DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4

  4/27/2021

  DURECT Corporation  (Nasdaq: DRRX) today announced that it will report its first quarter 2021 financial results and host a conference call after the market close on Tuesday, May 4, 2021 . Tuesday, May 4 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time

• 

  Get to Know Norman Sussman, Chief Medical Officer at DURECT

  4/22/2021

  BioSpace recently spoke with Norman Sussman, chief medical officer at DURECT, a company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.

• DURECT Corporation Announces Publication of DUR-928's Mechanism of Action

  3/9/2021

  DUR-928 is an inhibitor of DNA methyltransferases (DNMTs) regulating expression of genes involved in cell survival, inflammation and lipid biosynthesis

• DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs

  3/4/2021

  DURECT Corporation announced financial results for the three months and year ended December 31, 2020 and provided a corporate update.

• DURECT Corporation to Announce 2020 Financial Results and Provide Business Update on March 4

  2/25/2021

  DURECT Corporation announced that it will report its fourth quarter and year ended December 31, 2020 financial results and host a conference call after the market close on Thursday, March 4, 2021.

• DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis

  1/25/2021

  DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients.

• 

  BioSpace Movers & Shakers, Jan. 8

  1/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• DURECT Corporation Appoints Two New Board Members

  1/5/2021

  DURECT Corporation announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.

• DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million

  1/4/2021

    DURECT Corporation  (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020 . About DURECT Corporation DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver disea

• DURECT Corporation to Participate in Investor Conferences in January 2021

  12/21/2020

  DURECT Corporation  (Nasdaq: DRRX) today announced that it will participate in the forthcoming H.C. Wainwright BioConnect 2021 Conference and Annual LifeSci Advisors Corporate Access Event. Both conferences w

• DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million

  12/7/2020

    DURECT Corporation  (Nasdaq: DRRX) today announced that it has signed an agreement to sell its LACTEL Absorbable Polymer (LACTEL) product line to Evonik, a global leader in specialty chemicals. Under the terms of the agreement, Evonik will pay DURECT $15 million in exchange for certain assets and liabilities associated with

• DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman

  11/10/2020

  DURECT Corporation announced that Norman Sussman, MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis, as well as information on DURECT' investigational drug candidate, DUR-928, being developed for the treatment of AH.

• 

  BioSpace Movers & Shakers, Nov. 6

  11/6/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs

  11/2/2020

  DURECT Corporation announced financial results for the three months ended September 30, 2020 and provided a corporate update.

• DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development"

  10/26/2020

  DURECT Corporation announced that it will partipate in the ROTH Capital Healthcare Event, "Covid-19 Therapeutics in Development," taking place on Wednesday, October 28, 2020.

• DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020

  10/5/2020

  DURECT Corporation (Nasdaq: DRRX) today announced it will present a poster at The AASLD Liver Meeting Digital Experience ™ (TLMdX) 2020 , to be held virtually on November 13-16 , 2020.  Topline results from the 4-week Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients wer